Home › Articles › Volume 15, Issue 3 › Recent Advances in The Management of Diabetic Macula...
Moradabad, India
Review Article

Recent Advances in The Management of Diabetic Macular Edema


Volume 15, Issue 3, Pages 17-19

Authors

Dhanisha JL1, Heber Anandan2, Akshaya3, Preethi Anie E4, Bharath Kumar S5, Harshal Sahare6, Jenesha Blessie K7, Jenefa Melcy Michael8
Affiliation:
1Associate Professor & Principal, Dr. Agarwal’s Eye Hospital, Tirunelveli, Tamil Nadu, India.
2Addl. DG of Research, Dr. Agarwal’s Eye Hospital, Tirunelveli, Tamil Nadu, India.
3Clinical Intern, Dr. Agarwal’s Eye Hospital, Tirunelveli, Tamil Nadu, India.
4Assistant Professor, Dr. Agarwal’s Eye Hospital, Tirunelveli, Tamil Nadu, India.
5Senior Lecturer, Dr. Agarwal’s Eye Hospital, Tirunelveli, Tamil Nadu, India.
6Consultant, Dr. Agarwal’s Eye Hospital, Tirunelveli, Tamil Nadu, India.
7Lecturer, Dr. Agarwal’s Eye Hospital, Tirunelveli, Tamil Nadu, India.
8Medical Writer, Dr. Agarwal’s Eye Hospital, Tirunelveli, Tamil Nadu, India.

Abstract

Diabetic macular oedema (DME) is a vision-threatening complication of diabetic retinopathy caused by breakdown of the retinal vascular barrier and accumulation of intraretinal or subretinal fluid. Optical coherence tomography (OCT) has transformed diagnosis and treatment monitoring. Intravitreal anti–vascular endothelial growth factor (anti-VEGF) therapy remains the principal treatment for centre-involving DME, but repeated injections create a substantial burden for patients and health-care systems. Recent developments aim to improve durability without compromising vision. Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, permits personalised dosing intervals of up to 16 weeks in appropriately responding eyes. The ranibizumab port-delivery system (PDS) provides continuous drug delivery with refill exchanges every 24 weeks and was noninferior to monthly ranibizumab in the PAGODA randomised trial. Corticosteroid implants remain useful in selected eyes, particularly when anti-VEGF response is inadequate, although cataract formation and intraocular-pressure elevation require careful monitoring. This review summarises current evidence, practical treatment considerations, limitations, and future directions in sustained drug delivery for DME.

Keywords

Anti-VEGF, Corticosteroid implant, Diabetic macular oedema, Diabetic retinopathy, Optical coherence tomography, Port-delivery system, Ranibizumab.

History

Received 18 August 2026

Revised 04 September 2026

Accepted 14 September 2026

Author Notes

Corresponding Author: Dhanisha JL, Associate Professor & Principal, Dr. Agarwal’s Eye Hospital, Tirunelveli, Tamil Nadu, India. Email:

Open Access

It is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC 4.0), Creative Commons license that lets people share, remix, and build upon a work, but only for non-commercial purposes and as long as they give credit to the original creator. https://creativecommons.org/licenses/by-nc/4.0/

Copyright

Copyright: © The author(s), 2026.

Cite this Article

Formats

                                                
Actions
Download PDF
Metrics
9
Downloads
36
Views
Journal
Journal Asian Journal of Medical Research
Volume Volume 15
Issue Issue 3
Year 2026

Purchase access plans

Select the plan that best fits your need

Loading plans...

Statistics:

Views: 0
Downloads: 0

Asian Journal of Medical Research (AJMR) is an international, peer-reviewed, quarterly open-access journal publishing advanced research across medical specialties.

Quick Links

For Authors

© 2026 Asian Journal of Medical Research. All Rights Reserved.Designed and Developed By Kryoni